Weekly Paclitaxel After Adjuvant FAC Offers Modest, but Clinically Relevant Improvement in Disease-Free Survival in Patients with High-Risk, Node-Negative Breast Cancer
Weekly Paclitaxel After Adjuvant FAC Offers Modest, but Clinically Relevant Improvement in Disease-F
CME
Program Description:
Adjuvant therapy including 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) followed by weekly paclitaxel was associated with a slight but significant improvement in disease-free survival versus FAC alone in patients with high-risk, node-negative breast cancer, according to results of the first efficacy analysis presented at the 2012 Annual Meeting of the American Society of Clinical Oncology.
Continue Reading
INTENDED AUDIENCE:
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with breast cancer.
Activity Objectives:
After participating in this educational activity, participants should be better able to:
Evaluate the role of a sequential weekly addition of paclitaxel to cytotoxic agent protocols in patients with high-risk node-negative breast cancer.
Identify the hematologic and nonhematologic toxicities associated with FAC and FAC-paclitaxel in high-risk node-negative breast cancer patients.
